The following report on Vinpocetine was conducted by the University of Michigan.
A double-blind trial found both 30 mg and 60 mg per day ofvinpocetine improved symptoms of dementia in patients with various brain diseases.1 Another double-blind trial gave 30 mg per day of vinpocetine for one month, followed by 15 mg per day for an additional two months, to people with dementia associated with hardening of the arteries of the brain, and significant improvement in several measures of memory and other cognitive functions was reported.2 Other double-blind trials have reported similar effects of vinpocetine in people with some types of dementia or age-related cognitive decline.3 , 4 However, a study of Alzheimer patients in the United States found vinpocetine given in increasing amounts from 30 mg to 60 mg per day over the course of a year neither reversed nor slowed the decline in brain function measured by a number of different tests
Vinpocetine given by intravenous injection has been reported to improve some biochemical measures of brain function in stroke patients.6 , 7 A controlled trial found intravenous vinpocetine given within 72 hours of a stroke reduced some of the losses in brain function that typically follow a stroke.8 However, the reliability of human stroke research using vinpocetine has been questioned,9 , 10and more double-blind trials are needed. No studies using oral vinpocetine for treating acute strokes have been published.
Read more at the following link http://www.uofmhealth.org/health-library/hn-3957003